News

Myeloid Therapeutics Initiates Patient Dosing with MT-302, a Novel TROP2-Targeting RNA CAR, in Phase 1 Study for Advanced or Metastatic Epithelial Tumors

Myeloid Therapeutics, a clinical-stage oncology company, has dosed the first patient with MT-302 in a Phase 1 study for advanced or metastatic epithelial tumors. MT-302 is the Company’s lead development candidate for in vivo immune cell programming and delivers TROP2-targeting RNA chimeric antigen...

Exai Bio Presents Data Further Validating its Liquid Biopsy Platform at the 2023 World Conference on Lung Cancer

Exai Bio today announced non-small cell lung cancer (NSCLC) data further validating that its novel RNA- and generative AI-based liquid biopsy platform detected early-stage disease with high accuracy. The study of nearly 900 subjects demonstrated stage I sensitivity was 95% at 90% specificity.

Viz.ai Signs License Agreement with UCSF to Commercialize Three Cardiac Artificial Intelligence Algorithms

Viz.ai, working in AI-powered disease detection and intelligent care coordination, today announced that it has signed an exclusive agreement with the University of California, San Francisco (UCSF) to commercialize three AI algorithms for the automated detection of cardiovascular diseases.

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

UCSF and ClearPoint Neuro announce partnership to develop an innovative cellular delivery platform from the lab of Dr. Daniel Lim, MD, PhD via an exclusive multi-year licensing agreement. Bringing together UCSF's technology with the ClearPoint system will enable precise and targeted therapeutic...

Foundery Announces Initial Close of Inaugural Biotech Venture Creation Fund to Accelerate the Development of Novel Immunotherapies

Foundery, a biotechnology venture studio focused on transla6ng immunology discoveries into drug candidates, today announced an initial close of its inaugural fund, Foundery I, LP (“Foundery Fund I”), with total capital commitments and contributed assets as of the closing equal to $29.6 million.

MindRhythm Announces Publication in JAMA Network Open of Novel Headset for Return to Play Decisions in Concussion

Novel, noninvasive, headset detects a newly discovered biometric that allows for objective identification of concussion and recovery. “Concussion is common in sports and returning to play before recovery can cause long-term neurological impairment or permanent brain injury,” said Cathra Halabi, MD...

Philanthropic endowments at universities can offer a way out of biotech’s Valley of Death

"A new idea now taking hold in academia offers the promise of a path out of the Valley of Death: Universities, whose labs are home to so many of these potentially life-changing discoveries, should raise a philanthropic endowment and use the money to fund the work of the scientists to advance their...

Ikena Oncology Acquires Pionyr Immunotherapeutics in All-Stock Transaction

Ikena Oncology, a targeted oncology company forging new territory in patient-directed cancer treatment, and Pionyr Immunotherapeutics, a privately-held, clinical-stage biotechnology company, today announced the closing of Ikena’s acquisition of Pionyr in an all-stock transaction.

Scalable Care Inc signs landmark license agreement with UCSF to commercialize evidence-based mental health resources

Scalable Care Inc signs an exclusive worldwide licensing agreement with UCSF to commercialize evidence-based digital mental health therapies that help teenagers and young adults manage emotions, cope with trauma, resolve interpersonal conflicts, and learn self-reflection using conversational AI and...

BeeKeeperAI Raises $12.1 Million Series A to Accelerate AI Development on Privacy Protected Healthcare Data

BeeKeeperAI, Inc., a pioneer in zero-trust, collaboration software for the development and deployment of artificial intelligence (AI), today announced that it has closed $12.1 million in Series A financing. The round was led by Santé Ventures, with participation from the Icahn School of Medicine at...